jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Dec. 13, 2011

Dec. 17, 2018

jRCT2080221670

Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer

Phase I/II trial of YHI-1003 plus Capecitabine

Yakult Honsha Co., Ltd.

TEL: +81-3-5550-8968, FAX: +81-3-3248-5502

50

Interventional

open-label, multicenter trial

1-2

(1)Patients with recurrent or metastatic colorectal cancer
(2)Patients must have failed available therapy for the treatment of advanced colorectal cancer.
(3)No prior exposure to capecitabine and S-1
(4)ECOG performance status (PS) :0-1

(1)Patients with uncontrolled intercurrent illness
(2)Female patients who are pregnant or lactating
(3)Patients with known central nervous system CNS metastases

20age old over
No limit

Both

Refractory Advanced Colorectal Cancer

investigational material(s)
Generic name etc : YHI-1003
INN of investigational material : Perifosine
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : oral

safety
CTCAE v4.0

efficacy and pharmacokinetic profile
RECIST ver1.1

Yakult Honsha Co.,Ltd.

JapicCTI-111712

History of Changes

No Publication date
6 Dec. 17, 2018 (this page) Changes
5 Mar. 27, 2013 Detail Changes
4 Mar. 27, 2013 Detail Changes
3 Jan. 27, 2012 Detail Changes
2 Dec. 15, 2011 Detail Changes
1 Dec. 13, 2011 Detail